Soligenix Q3 2025 Financial Results and Clinical Pipeline Updates FAQ
TL;DR
Soligenix's upcoming Phase 2a psoriasis results and Phase 3 CTCL trial progress offer potential investment advantages in the rare disease biopharmaceutical sector.
Soligenix reported Q3 2025 results with $10.5 million cash extending operations through 2026 while advancing Phase 2a and Phase 3 clinical trials.
Soligenix's treatments for rare diseases like CTCL and psoriasis address unmet medical needs, potentially improving patient outcomes and quality of life worldwide.
Soligenix uses novel photodynamic therapy with safe visible light to treat CTCL, representing an innovative approach in biopharmaceutical development.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix reported its third quarter 2025 financial results and outlined upcoming clinical milestones, including top-line Phase 2a results for SGX302 in psoriasis and an enrollment update for the confirmatory Phase 3 HyBryte™ study in cutaneous T-cell lymphoma (CTCL).
The first Data Monitoring Committee review found no safety concerns for HyBryte™, maintaining a consistent safety profile across trials according to CEO Christopher J. Schaber, PhD.
Soligenix had $10.5 million in cash as of September 30, 2025, and expects its operating runway to extend through 2026 while evaluating strategic options to advance its late-stage pipeline.
The segment includes HyBryte™ (SGX301) for CTCL, SGX302 for psoriasis, dusquetide (SGX942) for inflammatory diseases including oral mucositis, and SGX945 for Behcet's Disease.
The segment includes RiVax® ricin toxin vaccine, filovirus vaccines (Marburg and Ebola), CiVax™ COVID-19 vaccine, all incorporating the proprietary ThermoVax® heat stabilization technology.
This business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agency (DTRA), and the Biomedical Advanced Research and Development Authority (BARDA).
Investors should watch for top-line Phase 2a results for SGX302 in psoriasis and enrollment updates for the confirmatory Phase 3 HyBryte™ study in CTCL.
The latest news and updates relating to SNGX are available in the company's newsroom at https://ibn.fm/SNGX.
HyBryte™ (SGX301 or synthetic hypericin sodium) is a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
This indicates the company is advancing treatments for rare diseases with unmet medical need that are in later stages of clinical development, closer to potential regulatory approval and commercialization.
Curated from InvestorBrandNetwork (IBN)
